99 related articles for article (PubMed ID: 29464055)
1. [Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration.
Booth L; Roberts JL; Rais R; Kirkwood J; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Oncotarget; 2018 Jan; 9(5):6062-6074. PubMed ID: 29464055
[TBL] [Abstract][Full Text] [Related]
2. The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.
Booth L; Roberts JL; Poklepovic A; Kirkwood J; Sander C; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
Cancer Biol Ther; 2018 Feb; 19(2):132-137. PubMed ID: 29219657
[TBL] [Abstract][Full Text] [Related]
3. HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody
Booth L; Roberts JL; Poklepovic A; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
Oncotarget; 2017 Oct; 8(52):90262-90277. PubMed ID: 29163826
[TBL] [Abstract][Full Text] [Related]
4. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
[TBL] [Abstract][Full Text] [Related]
5. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
[TBL] [Abstract][Full Text] [Related]
6. Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate].
Dent P; Booth L; Poklepovic A; Hoff DV; Hancock JF
Cell Signal; 2020 Apr; 68():109525. PubMed ID: 31911180
[TBL] [Abstract][Full Text] [Related]
7. Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells.
Dent P; Booth L; Roberts JL; Liu J; Poklepovic A; Lalani AS; Tuveson D; Martinez J; Hancock JF
Oncogene; 2019 Jul; 38(30):5890-5904. PubMed ID: 31253872
[TBL] [Abstract][Full Text] [Related]
8. Neratinib augments the lethality of [regorafenib + sildenafil].
Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Hancock JF; Poklepovic A; Dent P
J Cell Physiol; 2019 Apr; 234(4):4874-4887. PubMed ID: 30203445
[TBL] [Abstract][Full Text] [Related]
9. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
Booth L; Roberts JL; Samuel P; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Jun; 19(6):525-533. PubMed ID: 29405820
[TBL] [Abstract][Full Text] [Related]
10. Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition.
Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(2):157-168. PubMed ID: 30183517
[TBL] [Abstract][Full Text] [Related]
11. The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib.
Booth L; Roberts JL; Poklepovic A; Dent P
Front Oncol; 2019; 9():650. PubMed ID: 31380285
[TBL] [Abstract][Full Text] [Related]
12. Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells.
Booth L; Roberts JL; Kirkwood J; Poklepovic A; Dent P
Adv Cancer Res; 2018; 137():1-15. PubMed ID: 29405973
[TBL] [Abstract][Full Text] [Related]
13. HDAC inhibitors enhance the immunotherapy response of melanoma cells.
Booth L; Roberts JL; Poklepovic A; Kirkwood J; Dent P
Oncotarget; 2017 Oct; 8(47):83155-83170. PubMed ID: 29137331
[TBL] [Abstract][Full Text] [Related]
14. NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells.
Booth L; Roberts JL; Poklepovic A; Dent P
Oncol Signal; 2018 Jun; 1(1):19-30. PubMed ID: 30740589
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies.
Dent P; Booth L; Poklepovic A
Immunometabolism; 2020; 2(1):. PubMed ID: 31885880
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
[TBL] [Abstract][Full Text] [Related]
17. Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
Schwab CL; English DP; Roque DM; Bellone S; Lopez S; Cocco E; Nicoletti R; Rutherford TJ; Schwartz PE; Santin AD
Gynecol Oncol; 2014 Oct; 135(1):142-8. PubMed ID: 25124161
[TBL] [Abstract][Full Text] [Related]
18. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
[TBL] [Abstract][Full Text] [Related]
19. A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments.
Seyhan AA; Varadarajan U; Choe S; Liu Y; McGraw J; Woods M; Murray S; Eckert A; Liu W; Ryan TE
Mol Biosyst; 2011 Jun; 7(6):1974-89. PubMed ID: 21487605
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of oncogenic N-ras-induced neurite outgrowth and ornithine decarboxylase activity by phorbol dibutyrate and protein kinase inhibitor H-8.
Trotta RJ; Thomson TM; Lacal JC; Pellicer A; Burstein DE
J Cell Physiol; 1990 Apr; 143(1):68-78. PubMed ID: 2180965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
